Parallel trade, GSK and the ECJ: the beauty of equivocation
This article was originally published in RAJ Devices
Executive Summary
The European Court of Justice (ECJ) Judgement in the recent GlaxoSmithKline versus Greek wholesalers case smacks of little more than fence-sitting, suggests Edward Miller, Partner at international law firm Reed Smith. “I think the legal arguments that the Court has come up with are slightly different than the ones that have been kicked around before, but I think that the practical consequence of it is that it is going to change very little,” Mr Miller told EURALex.
You may also be interested in...
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
EMA Acts To Freeze GVK Drugs, Guard Against Shortages
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.
EMA Acts To Freeze Drugs Linked to GVK Bio, Guards Against Shortages
EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.